BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition
BostonGene will present six abstracts at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9, 2025, in Orlando, Florida, including two oral presentations, three poster presentations, and one online publication.
The company’s AI-powered platform integrates whole exome sequencing and RNA sequencing of tumor and peripheral blood samples, specifically analyzing CD138⁺ plasma cells in multiple myeloma.
BostonGene’s approach reproduces known abnormalities detected by FISH (such as del17p/TP53 deletion and t(11;14) translocations) and additionally reveals mutations, structural variants, and immune signatures, even in low-tumor-content samples, potentially offering broader and scalable diagnostic capabilities beyond conventional methods.
Their AI tools, including the Lymphly classifier and B-cell-based markers, enhance patient stratification and molecular precision to de-risk clinical programs and support development of effective companion diagnostics and unified monitoring in drug studies.
These advances signify a move beyond traditional diagnostic methods towards an integrated, foundational approach leveraging multiomic data and AI to improve therapeutic targeting and clinical trial design in hematologic malignancies.
BostonGene’s broader efforts include validated multimodal AI platforms that combine deep molecular profiling, immune system characterization, and advanced analytics to accelerate oncology drug development and improve patient care across multiple tumor types.